Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis SOUTH SAN FRANCISCO, Calif., September 14, 2020 – Attralus, a biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis, today announced the completion of its […]
